Zacks Investment Research
04 Nov 2026, 23:51 UTC · 2h ago
Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates
Impact · against what's priced in
Bio-Rad's Q3 results show a modest earnings beat and flat revenue growth. While the bottom-line efficiency is positive, the marginal revenue increase suggests a lack of strong top-line catalysts.
- BIO+0.10
No priced-in read yet
- In context
The company beat earnings estimates with $2.65 per share versus $2.61 expected, though revenue was nearly flat year-over-year at $656.4 million.
Read from the article alone
Search tags
